Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
Portfolio Pulse from Benzinga Insights
AstraZeneca (NASDAQ:AZN) is analyzed in comparison to its competitors in the Pharmaceuticals industry. The company's financial metrics such as P/E, P/B, P/S, ROE, EBITDA, gross profit, and revenue growth are evaluated. AstraZeneca's P/E of 33.42, P/B of 5.26, and P/S of 4.38 are below the industry averages, suggesting undervaluation. However, its ROE of 3.68% and revenue growth of 4.64% are significantly lower than the industry averages, indicating potential inefficiencies and struggles in sales volume growth. AstraZeneca's lower debt-to-equity ratio compared to its top 4 peers suggests a stronger financial position with less reliance on debt financing.
November 13, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's financial metrics indicate undervaluation with lower P/E, P/B, and P/S ratios compared to industry averages, but its lower ROE and revenue growth raise concerns about profitability and sales volume growth.
The undervaluation suggested by P/E, P/B, and P/S ratios could attract investors looking for growth opportunities, potentially having a positive impact on the stock price. However, the lower ROE and revenue growth compared to the industry might temper investor enthusiasm, leading to a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100